Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06153173 · ClinicalTrials.gov registry record · Phase 2
Mirdametinib in Histiocytic Disorders
A Phase 2 study of Histiocytic Disorders and Langerhans Cell Histiocytosis (LCH), sponsored by Children's Hospital Medical Center, Cincinnati.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT06153173: Recruiting Phase 2 study of Histiocytic Disorders and Langerhans Cell Histiocytosis (LCH), sponsored by Children's Hospital Medical Center, Cincinnati.
NCT06153173 is a Phase 2 study of Histiocytic Disorders and Langerhans Cell Histiocytosis (LCH) that is actively recruiting participants, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 40 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06153173, a Phase 2 study of Histiocytic Disorders and Langerhans Cell Histiocytosis (LCH), is actively recruiting participants, sponsored by Children's Hospital Medical Center, Cincinnati.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to see if treatment with mirdametinib in patients with Langerhans cell histiocytosis (LCH) or other histiocytic disorders will be better than current treatments and with fewer side effects.
Primary Outcome
Best overall response rate to mirdametinib after 13 four-week cycles as defined by positron emission tomography (PET) or magnetic resonance imaging (MRI) (for isolated pituitary/central nervous system (CNS) disease) response criteria.
Conditions Studied
Interventions
- DRUG Mirdametinib
Study Locations (1)
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2024-02-05 |
| Est. Completion | 2031-03 |
| Phase | Phase 2 |
What NCT06153173 shows while recruiting
NCT06153173 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (70% lower).
The record links to 4 conditions, with Histiocytic Disorders appearing as the primary indexed condition, and to 1 intervention - of which Mirdametinib is the first listed.
NCT06153173 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT06153173 about?
NCT06153173 is a clinical study titled "Mirdametinib in Histiocytic Disorders". The purpose of this study is to see if treatment with mirdametinib in patients with Langerhans cell histiocytosis (LCH) or other histiocytic disorders will be better than current treatments and with fewer side effects.
What is the current status of trial NCT06153173?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2024-02-05. Estimated completion is 2031-03.
What conditions does trial NCT06153173 study?
This clinical trial studies the following conditions: Histiocytic Disorders, Langerhans Cell Histiocytosis (LCH), Rosai-Dorfman Disease (RDD), Juvenile Xanthogranuloma (JXG).
What interventions are being tested in trial NCT06153173?
The interventions under investigation include: Mirdametinib (DRUG).
Who is sponsoring clinical trial NCT06153173?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06153173 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Histiocytic Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06153173's enrollment target sits among peer trials
40 1362nd of 2000 higher than 542 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI